Table 1 Characteristics of studies included in the network meta-analysis
First author, year | Country | Inclusion criteria of T2DM | T2DM duration (year) | T2DM treatment | Age (years) | Female/male | Intervention | Control |
|---|---|---|---|---|---|---|---|---|
Singh (2008) [25] | India | T2DM | na | na | > 30 | na | A: SRP + Doxy (100 mg bid for day 1 and then 100 mg/day for 13 days) (n = 15) B: SRP (n = 15) | No treatment (n = 15) |
Gilowski (2012) [26] | Poland | T2DM diagnosed for > 6 months | T: 4.0 (1.5–13.0) C: 5.0 (3.0–18.0) | diet regimen, insulin, and or oral hypoglycemic drugs | T: 57.6 ± 8.0 C: 56.0 ± 9.0 | T: 10/ 7 C: 8/ 9 | SRP + SDD (20 mg bid for 3 months) (n = 17) | SRP + placebo (n = 17) |
Moeintaghavi (2012) [27] | Iran | Diagnosis of T2DM with glycated HbA1c values over 7% | na | oral hypoglycemic drugs (no insulin) | Female: 48.1 ± 3 Male: 52.48 ± 3 | T: 13/ 9 C: 7/ 11 | SRP (n = 22) | No treatment (n = 18) |
Gaikwad (2013) [28] | India | T2DM | na | Received antidiabetic therapy | na | 16/ 34 | SRP + Doxy (100 mg/d for15 days) (n = 25) | SRP (n = 25) |
Pradeep (2013) [29] | India | Well-controlled type 2 DM (American Diabetic Association in 2011 and glycated hemoglobin levels) | na | na | 30 - 50 | 18/ 20 | SRP + SMV gel (1.2%) (n = 17) | SRP + placebo (n = 18) |
Santos (2013) [30] | Brazil | T2DM diagnosed > 5 years | T: 6.3 ± 0.8 C: 6.8 ± 1.1 | Diet: 1/ 0 Diet + insulin: 1/ 4 Diet + oral hypoglycemic agents: 14/ 14 Diet + oral hypoglycemic agents + insulin: 3/ 1 | T: 50.3 ± 9.5 C: 53.9 ± 10.8 | T: 15/ 4 C: 13/ 6 | SRP + CHX gel (1%) + CHX solution (0.12%) rinse (bid/day for 60 days) (n = 19) | SRP + placebo gel + placebo solutions rinse (n = 18) |
Telgi (2013) [31] | India | T2DM | na | oral hypoglycemic agents | 35 - 45 | na | A: SRP + 0.12% CHX mouthwash (once daily) and brush (twice daily) (n = 20) B: 0.12% CHX mouthwash (once daily) and brush (twice daily) (n = 20) | brush (twice daily) (n = 20) |
Macedo (2014) [11] | Brazil | T2DM diagnosed for >5 years and HbA1c >7 % | > 5 | na | T: 49.4 ± 6.8 C: 48.1 ± 9 | T: 9/ 6 C: 10/ 5 | SRP + aPDT (10 mg/ml PC) + Doxy (100 mg bid for day 1 and then 100 mg/day for 13 days) (n = 15) | SRP + Doxy (100 mg bid for day 1 and then 100 mg/day for 13 days) (n = 15) |
Miranda (2014) [32] | Brazil | T2DM diagnosed for ≥ 5 years, HbA1c ≥ 6.5% ≤ 11% | T: 8.0 ± 3.2 C: 7.4 ± 3.6 | Diet and insulin supplementation or oral hypoglycemic agents | T: 54.0 ± 8.2 C: 53.7 ± 8.0 | T: 17/ 12 C: 9/ 18 | SRP + MTZ + AMX (400/500 mg tid for 14 days) (n = 29) | SRP + placebos (n = 27) |
Tsalikis (2014) [33] | Greece | T2DM diagnosed for ≥ 1 year | T: 11.8 ± 5.9 C: 10.2 ± 5.7 | na | T: 62.9 ± 10 C: 57.94 ±8.22 | T: 13/ 18 C: 15/ 20 | SRP+ Doxy (100 mg bid for day 1 and then 100 mg/day for 20 days) (n = 31) | SRP + placebos (n = 35) |
Wu (2015) [34] | China | T2DM diagnosed for > 1 year with no medication changes in the last 3 months | T: 4.00 ± 1.76 C: 4.22 ± 1.57 | na | T: 54.09 ±6.57 C: 55.52 ±5.22 | T: 12/11 C: 10/13 | SRP + OHI (n = 23) | OHI (n = 23) |
Koçak (2016) [35] | Turkey | TDM2 (5.7 % ≤ glycated hemoglobin (HbA1c) ≤8.5 %) with no alteration in the diabetes treatment in the last year prior to the study | Na | na | T: 51.7 ± 5.2 C: 53.1 ± 5.1 | T: 15/15 C: 15/15 | SRP + DL (n = 30) | SRP (n = 30) |
Kumari (2016) [10] | India | Well-controlled T2DM (American Diabetic Association in 2012 and glycated hemoglobin Levels) | Na | na | 40-50 | 37/38 | SRP + ATV gel (1.2%) (n = 30) | SRP + placebo gel (n = 30) |
Ramos (2016) [36] | Brazil | Type 2 DM diagnosed for > 5 years and HbA1c >7% | >5 | na | T: 48.9 ± 9.5 C: 49.3 ± 7.4 | T: 8/7 C: 8/7 | SRP + aPDT (10 mg/ml PC) (n = 15) | SRP + Doxy (100 mg bid for day 1 and then 100 mg/day for 13 days) (n = 15) |